Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
116. |
ECCT/21/12/07 | GBT 132- Inclacumab Phase 3 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises. |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Videlis N Nduba 3. Fredrick Asirwa Chite Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 3. KEMRI/CRDR (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) |
View |
117. |
ECCT/21/12/05 | 131 Inclacumab Ph 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Fredrick Asirwa Chite 3. Videlis N Nduba 4. Prof. Jessie N Githanga Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrude’s Children’s Hospital. (Nairobi City county) 5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) |
View |
118. |
ECCT/21/11/08 | GBT_131 Inclacumab-Ps 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises |
Principal Investigator(s) 1. Videlis N Nduba 2. Prof. Jessie N Githanga 3. Fredrick Sirwa Chite 4. Bernhards Ragama Ogutu Site(s) in Kenya 1. KEMRI/CRDR (Nairobi City county) 2. KEMRI Siaya Clinical Research Annex (Siaya county) 3. Gertrude’s Children’s Hospital. (Nairobi City county) 4. Strathmore University Medical Centre (Nairobi City county) 5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) |
View |
119. |
ECCT/21/11/07 | lidERA A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTORï€POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER |
Principal Investigator(s) 1. Fredrick Asirwa Chite Site(s) in Kenya 1. International Cancer Institute (ICI) (Uasin Gishu county) 2. Aga Khan University Hospital (Nairobi City county) |
View |
120. |
ECCT/21/11/04 | GBT_131 Inclacumab-Ps 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises |
Principal Investigator(s) 1. Fredrick Sirwa Chite 2. Prof Jessie N Githanga 3. Bernhards Ragama Ogutu 4. Videlis N Nduba Site(s) in Kenya 1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrude’s Children’s Hospital. (Nairobi City county) 5. Strathmore University Medical Centre (Nairobi City county) |
View |